Thank you for sharing!

Your article was successfully shared with the contacts you provided.

With the U.S. Supreme Court holding last year in Pliva, Inc. v. Mensing that the manufacturer of a generic pharmaceutical product cannot be liable under a failure-to-warn theory, pharmaceutical plaintiffs are searching for new theories to hold nonmanufacturers liable for alleged injuries. The 2009 case Conte v. Wyeth Inc., et al. was widely publicized for allowing plaintiffs injured by a generic pharmaceutical to hold the “innovator,” or brand-name manufacturer, liable even though it did not manufacture the product, but Conte has not found favor with other courts. In the wake of Mensing and Conte’s failure to gain traction, one has to wonder which nonmanufacturer is the next target.

ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2017 ALM Media Properties, LLC. All Rights Reserved.